Close Menu

More articles about Infectious Disease

Ortho said that it currently can deliver 5 million tests per month and will be able to increase that figure to 15 million tests per month in February.

The lateral flow test can be used at the point of care and provides results within 15 minutes without the need for additional equipment, the company said.

During the quarter, the Tucson, Arizona-based company added 45 instruments for a total of 268 revenue-generating instruments installed in the US.

Separately, Siemens said that it has received CE marking for the use of its Clinitest Rapid COVID-19 Antigen Test with an additional specimen type.

For full-year 2020, the company expects revenues of approximately $417 million, which would be up 25 percent from a year ago.

The company said that in Q4 it placed 70 net new ePlex analyzers and finished the year with a global installed base of 792 analyzers.

The assay can be used to determine the immune status of COVID-19 patients and individuals who have been vaccinated against the virus, the company said.

The government said that rapid, regular testing of asymptomatic patients will be expanded to cover all 317 local authorities in the country starting next week.

The agency identified three tests potentially impacted by known mutations, and said it will continue to monitor authorized assays.

The firm's Diagnostics division expects to post $1.13 billion in revenues for fiscal Q1 2021, up 262 percent from $312.0 million in the year-ago period.

Biodesix, which raised about $63 million in a recent initial public offering, said it ended 2020 with roughly $62 million in cash and cash equivalents.

Some tests that detect multiple SARS-CoV-2 genes are serendipitously signaling new viral variants while still effectively detecting infections.

One of a host of new methods used for diagnosis of and screening for COVID-19, there are still hurdles to widespread adoption of breath testing for the disease.

Quidel reported preliminary fourth quarter revenues of $808 million to $810 million, compared to $152.2 million in Q4 2019.

The firm noted that interleukin-6 ─ an intercellular messenger molecule ─ is an indicator of the potential for a severe inflammatory response in patients with confirmed SARS-CoV-2 infection.

The collaboration builds on an oligonucleotide supply agreement the partners signed in 2019 for Clear Labs' nanopore sequencing-based food safety testing.

The test will identify more than 100 pathogens, as well as drug resistance in viruses and bacteria.

The deal will enable PerkinElmer to grow its infectious disease testing portfolio to include latent tuberculosis detection, it said.

The company's automated immunoassay is designed to qualitatively detect the SARS-CoV-2 nucleocapsid protein antigen in nasopharyngeal swab specimens.

Not every company in the 360Dx Index had significant gains, but multiple companies saw their share prices double.